Jay Mohr
Directeur/Membre du Conseil chez Mesentech, Inc.
Profil
Jay Mohr serves as General Partner of NYBC Ventures.
Jay is an accomplished entrepreneur and life science transaction specialist with more than three decades of experience in biopharma.
He also serves as Executive Vice President at New York Blood Center, where he also oversees Comprehensive Cell Solutions, a CDMO focusing on cellular therapy development and manufacturing.
Jay has held the position of CEO for two venture-capital-backed companies, Gloucester Pharmaceuticals and Variagenics, Inc., that both resulted in successful exits for shareholders.
He was founding CEO of Gloucester, a hematology therapeutics company acquired by Celgene.
Subsequent to Gloucester, Jay co-founded Locust Walk Partners, a global transaction advisory firm for the life sciences.
Jay currently serves as the Chairman of the Board of the T1D Exchange and is a Director on the Boards of Mesentech and the Maine Technological Institute.
He holds an MBA from The Wharton School of the University of Pennsylvania and a BA in economics and German from Vanderbilt University.
Postes actifs de Jay Mohr
| Sociétés | Poste | Début |
|---|---|---|
New York Blood Center, Inc.
 New York Blood Center, Inc. Medical/Nursing ServicesHealth Services New York Blood Center, Inc. operates blood distribution and research organizations. It provides blood and blood products for transfusions annually. The company was founded in 1964 and is located in New York, NY. | Private Equity Investor | 01/08/2020 |
Nybc Ventures
 Nybc Ventures Investment ManagersFinance NYBC Ventures (NYBC Ventures) is a venture capital subsidiary of New York Blood Center Inc founded in 2022. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/12/2022 |
Mesentech, Inc.
 Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Directeur/Membre du Conseil | 01/09/2020 |
Anciens postes connus de Jay Mohr
| Sociétés | Poste | Fin |
|---|---|---|
AZTherapies, Inc.
 AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Directeur des opérations | 01/08/2020 |
Locust Walk Partners LLC
 Locust Walk Partners LLC Miscellaneous Commercial ServicesCommercial Services Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA. | Fondateur | 01/01/2016 |
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Corporate Officer/Principal | 01/01/2008 |
Variagenics, Inc.
 Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Directeur Général | 01/01/2003 |
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Private Equity Investor | 01/01/2001 |
Formation de Jay Mohr
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology AZTherapies, Inc. engages in the development of therapeutics for Alzheimer’s disease and ischemic stroke treatments. Its product pipelines include ALZT-OP1, ALZT-OP2, AZHALER-D, and ALZT-QoL. The company was founded by David R. Elmaleh in 2011 and is headquartered in Boston, MA. | Health Technology |
New York Blood Center, Inc.
New York Blood Center, Inc. Medical/Nursing ServicesHealth Services New York Blood Center, Inc. operates blood distribution and research organizations. It provides blood and blood products for transfusions annually. The company was founded in 1964 and is located in New York, NY. | Health Services |
Nybc Ventures
Nybc Ventures Investment ManagersFinance NYBC Ventures (NYBC Ventures) is a venture capital subsidiary of New York Blood Center Inc founded in 2022. The firm is headquartered in Boston, Massachusetts. | Finance |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Health Technology |
Locust Walk Partners LLC
Locust Walk Partners LLC Miscellaneous Commercial ServicesCommercial Services Locust Walk Partners LLC provides commercial supporting and advisory services. The firm involves in securities-related transactions for clients, including mergers and acquisitions, private placements & mezzanine financings and partnerships involving equity investments. The company was founded by Geoff Meyerson and Joseph Mohr in 2008 and is headquartered in Boston, MA. | Commercial Services |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Health Technology |
Variagenics, Inc.
Variagenics, Inc. Miscellaneous Commercial ServicesCommercial Services Variagenics, Inc. develops molecular diagnostic tests by identifying genetic markers associated with response to cancer therapies, with the goal of optimizing patient care through both biopharmaceutical collaborations and its own internal research programs | Commercial Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
